LXEO · NASDAQ
Lexeo Therapeutics, Inc.
$2.80 -0.10 (-3.29%)
Company overview
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company focused on hereditary and acquired diseases. The company develops LX2006, an AAVrh10-based gene therapy candidate for treating Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for treating arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for treating DSP cardiomyopathy; and LX2022, a gene therapy candidate for treating HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for treating APOE4 homozygous patients; LX1020, a gene therapy candidate for treating APOE4 homozygous patients; LX1021 for treating APOE4 homozygotes; and LX1004 for treating CLN2 Batten disease. The company was incorporated in 2017 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $230M
- Employees
- 75
- Headquarters
- New York City
- Website
- lexeotx.com
- CEO
- R. Nolan Townsend
- Listed
- November 3, 2023
- P/E
- -1.93
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$546,000
- Operating income
- -$97.8M
- EBITDA
- -$87.3M
- Net income
- -$87.5M
- EPS
- -$1.45
- Total assets
- $250M
- Total debt
- $7.4M
- Earnings yield
- -51.79%
LXEO
1D
NASDAQ
O2.79H2.83L2.73C2.80-0.10 (-3.29%)Vol140.90K